Volume 10, Number 1—January 2004
Research
Respiratory and Urinary Tract Infections, Arthritis, and Asthma Associated with HTLV-I and HTLV-II Infection
Table 1
Characteristics of the multicenter, prospective human T-lymphotropic virus (HTLV) cohort study populationa
| Characteristics | HTLV-I (n = 152) | HTLV-II (n = 387) | HTLV negative (n = 799) |
|---|---|---|---|
| Age (y) | No. (%) | No. (%) | No. (%) |
| 18–29 | 5 (3) | 11 (3) | 34 (4) |
| 30–39 | 28 (18) | 104 (27) | 171 (21) |
| 40–49 | 55 (36) | 168 (43) | 288 (36) |
| 50–59 | 32 (21) | 73 (19) | 175 (22) |
| >60 | 32 (21) | 31 (8) | 131 (16) |
| Sex | |||
| Male | 43 (28) | 102 (26) | 257 (32) |
| Female | 109 (72) | 285 (74) | 542 (68) |
| Race/ethnicity | |||
| Asian | 20 (13) | 8 (2) | 60 (8) |
| Black | 61 (40) | 125 (32) | 248 (31) |
| Hispanic | 9 (6) | 104 (27) | 150 (19) |
| Other | 1 (1) | 7 (2) | 30 (4) |
| White | 59 (39) | 140 (36) | 309 (39) |
| Unknown | 2 (1) | 3 (1) | 2 (0) |
| Education | |||
| High school or less | 45 (30) | 135 (35) | 129 (16) |
| Some college | 66 (43) | 195 (51) | 363 (46) |
| College | 30 (20) | 45 (12) | 181 (23) |
| College (>4 years) | 11 (7) | 11 (3) | 123 (15) |
| Income | |||
| <$30,000 | 46 (30) | 144 (38) | 167 (21) |
| $30,000–49,999 | 51 (34) | 120 (32) | 221 (28) |
| >$50,000 | 55 (36) | 113 (30) | 401 (51) |
| Center | |||
| 1 | 32 (21) | 51 (13) | 122 (15) |
| 2 | 29 (19) | 39 (10) | 102 (13) |
| 3 | 44 (29) | 206 (53) | 345 (43) |
| 4 | 31 (20) | 68 (18) | 156 (20) |
| 5 | 16 (11) | 23 (6) | 74 (9) |
| Blood donor type | |||
| Autologous | 28 (18) | 39 (10) | 111 (14) |
| Allogeneic | 124 (82) | 348 (90) | 688 (86) |
| Smoking history (pack/y) | |||
| Nonsmoker | 74 (52) | 125 (36) | 413 (54) |
| 0–13 | 24 (17) | 117 (33) | 184 (24) |
| >13 | 43 (31) | 109 (31) | 174 (23) |
| Alcohol intake (average drinks per wk) | |||
| Nondrinker | 19 (13) | 20 (6) | 70 (9) |
| 0–1 | 58 (41) | 134 (38) | 352 (46) |
| >1 | 64 (45) | 200 (57) | 339 (45) |
| Lifetime sex partners | |||
| <6 | 56 (38) | 87 (23) | 381 (49) |
| >6 | 92 (62) | 292 (77) | 403 (51) |
| Injection drug use | |||
| Ever | 148 (98) | 294 (76) | 787 (99) |
| Ex-injection drug user | 2 (1) | 75 (19) | 9 (1) |
| Current injection drug user | 1 (1) | 17 (4) | 1 (0) |
aMissing data (up to 6%, depending upon the variable) were excluded from the calculation of percentages.
Page created: December 21, 2010
Page updated: December 21, 2010
Page reviewed: December 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.